Dyslipidemia, Vascular Atheroma and Statins

Author(s): Ahmed Abuzaid, Ayman El-Menyar

Journal Name: Current Vascular Pharmacology

Volume 13 , Issue 6 , 2015

Become EABM
Become Reviewer


Dyslipidemia plays an important role in the initiation and progression of atherosclerotic coronary artery disease. However, regression of atherosclerotic atheroma by introducing lipid lowering agents is not fully understood but looks promising. More questions still need to be answered in terms of the modality of assessment, time course of changes and its documentation, whether plaque progression or regression assessed by imaging one arterial tree reflects a uniform effect throughout all arterial territories and whether atheroma regression is a therapeutic goal. Physicians need to define the type of statins, the use of statin as monotherapy or in combination with other agents, and the intensity of statin therapy. Furthermore, the impact of factors like age, gender and ethnicity on the regression process should be of consideration. We still need more randomized controlled studies based on evidence-based diagnostic interventional tools. This narrative review considers this debate.

Keywords: Atheroma, coronary artery disease, atherosclerosis, lipids, statins, regression.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Page: [701 - 715]
Pages: 15
DOI: 10.2174/1570161112666141029224451
Price: $65

Article Metrics

PDF: 30